

	<b>N (percentage) / Median (range)</b>
<b>Median follow-up time (months)<sup>#</sup></b>	75.5
<b>Sex</b>	
<i>Male</i>	263 (50)
<i>Female</i>	261 (50)
<b>Age</b>	46.5 (15.0 – 77.0)
<b>Age group</b>	
< 60	460 (88)
> 60	64 (12)
<b>HOVON protocol</b>	
<i>04 / 04A</i>	99 (19)
<i>29</i>	213 (41)
<i>32</i>	5 (1)
<i>42</i>	148 (28)
<i>43</i>	59 (11)
<b>Type of stem cell transplant</b>	
<i>None</i>	299 (57)
<i>Autologous</i>	70 (13)
<i>Allogeneic</i>	150 (29)
<i>Unknown</i>	5 (1)
<b>WBC (x 10<sup>9</sup>/L)</b>	28 (0 – 510)
<b>Blasts in bone marrow (%)</b>	65 (0 – 98)
<b>Platelets (x 10<sup>9</sup>/L)</b>	55 (3 – 998)
<b>FAB</b>	
<i>M0</i>	18 (3)
<i>M1</i>	105 (20)
<i>M2</i>	127 (24)
<i>M3</i>	25 (5)
<i>M4</i>	87 (17)
<i>M5</i>	114 (22)
<i>M6</i>	7 (1)
<i>RAEB-t</i>	19 (4)
<i>RAEB</i>	4 (1)
<i>M4E</i>	5 (1)
<i>Unknown</i>	13 (2)
<b>Cytogenetic risk group</b>	
<i>Good</i>	103 (20)
<i>Intermediate</i>	305 (56)
<i>Poor</i>	104 (20)
<i>Unknown</i>	12 (2)
<b>Cytogenetics<sup>†</sup></b>	
<i>Normal cytogenetics</i>	214 (41)
<i>t(15;17)</i>	25 (5)
<i>t(8;21)</i>	37 (7)
<i>Inv(16)</i>	41 (8)

<b>11q23</b>	22 (4)
<b>3q</b>	20 (4)
<b>-5(q)</b>	16 (3)
<b>-7(q)</b>	37 (7)
<b>+chr8</b>	37 (7)
<b>Complex karyotype</b>	33 (6)
<b>Other cytogenetic abnormality</b>	130 (25)
<b>Molecular abnormalities<sup>†</sup></b>	
<b>FLT3-ITD</b>	141 (27)
<b>FLT3-TKD</b>	53 (10)
<b>NPM1</b>	157 (30)
<b>NRAS</b>	50 (10)
<b>KRAS</b>	5 (1)

Numbers of cases or median (range) are depicted where appropriate.

WBC indicates white blood cell count; and, FAB, French-American-British classification.

<sup>#</sup> Median follow-up time is given for patients alive at last follow-up.

<sup>†</sup> Each abnormality was taken into account, irrespective of the presence of other abnormalities.